keyword
MENU ▼
Read by QxMD icon Read
search

Zemplar

keyword
https://www.readbyqxmd.com/read/27470251/the-association-of-mineral-metabolism-with-vascular-access-patency
#1
Joel E Rosenberg, Brad C Astor, Hector F Deluca, Alexander S Yevzlin
BACKGROUND: Declining kidney function leads to progressively dysregulated mineral homeostasis and contributes to vascular calcification and a pro-inflammatory milieu, both of which play a critical role in loss of dialysis vascular access patency. We designed this study to examine the relationship between markers of bone and mineral metabolism, vitamin D replacement medications, and vascular access outcomes. We hypothesized that higher levels of calcium, phosphorous, parathyroid hormone (PTH), and albumin are independently associated with vascular access patency and that vitamin D supplementation is associated with lower risk of access failure...
September 21, 2016: Journal of Vascular Access
https://www.readbyqxmd.com/read/21849802/differential-effects-of-oral-doxercalciferol-hectorol-or-paricalcitol-zemplar-in-the-cyp27b1-null-mouse-model-of-uremia
#2
René St-Arnaud, Alice Arabian, Omar Akhouayri, Joyce C Knutson, Stephen A Strugnell
BACKGROUND/AIMS: Kidney disease patients experience declining calcitriol levels and develop secondary hyperparathyroidism (SHPT). Animal models of uremia based on 5/6 nephrectomy (NTX) do not consistently reproduce this calcitriol deficiency. We developed an animal model, the NTX Cyp27b1-null mouse, which completely lacks endogenous calcitriol, and examined the suitability of this model for evaluation of treatment with vitamin D analogs in uremia. METHODS: NTX was performed at 2 months of age...
2011: Nephron. Experimental Nephrology
https://www.readbyqxmd.com/read/21786580/-the-role-of-d2-vitamin-metabolite-paricalcitol-in-nephroprotective-strategy-in-chronic-disease-of-the-kidneys
#3
REVIEW
Iu S Milovanov, L V Kozlovskaia, L Iu Milovanova
Calcitriol is important in nephroprotective strategy in chronic disease of the kidneys (CDK). However, its long-term use often results in hypercalciemia with metastatic calcification. Compared to calcitriol, paricalcitol (zemplar)--metabolite of vitamin D2--leads to hypercalciemia less frequently, has a more potent nephroprotective effect and more rapidly decreases blood levels of parathyroid hormone. Paricalcitol in combination with lozartan has more pronounced nephroprotective effect. Morphological analysis detected inhibition of development of glomerulosclerosis and tubulointerstitial fibrosis...
2011: Terapevticheskiĭ Arkhiv
https://www.readbyqxmd.com/read/18616960/2-methylene-19-nor-20-s-1alpha-hydroxy-bishomopregnacalciferol-20-s-2mbisp-an-analog-of-vitamin-d3-1-25-oh-2d3-does-not-stimulate-intestinal-phosphate-absorption-at-levels-previously-shown-to-suppress-parathyroid-hormone
#4
Katie B Williams, Hector F DeLuca
Chronic kidney disease results in a reduction in 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) synthesis and an accumulation of phosphorus in the blood, leading to secondary hyperparathyroidism and renal osteodystrophy. Vitamin D analogs that retain the ability to suppress PTH but that are less calcemic and phosphatemic than the native hormone are preferred therapies for secondary hyperparathyroidism. However, even the most favored analog currently approved for the treatment of chronic kidney disease patients, i.e...
November 2008: Steroids
https://www.readbyqxmd.com/read/17163297/health-economic-comparison-of-paricalcitol-calcitriol-and-alfacalcidol-for-the-treatment-of-secondary-hyperparathyroidism-during-haemodialysis
#5
REVIEW
Hubertus Rosery, Rito Bergemann, Steven E Marx, Axel Boehnke, Joel Melnick, Raimund Sterz, Laura Williams
This study evaluated the health-economic consequences of use of intravenous paricalcitol (Zemplar), oral calcitriol or oral and intravenous alfacalcidol for the treatment of patients with secondary hyperparathyroidism, focusing on a third-party payer perspective through inclusion of medication and hospital costs, survival rates and utilities. Cost values were based on German treatment recommendations and prices. Reference values for survival rates and utilities were based on the results of a MEDLINE search...
2006: Clinical Drug Investigation
https://www.readbyqxmd.com/read/16534233/the-effect-of-hepatic-insufficiency-on-the-safety-and-pharmacokinetics-of-paricalcitol-zemplar
#6
Robert A Carr, Amy K André, Ping Chen, Brian A Grabowski, Min S Chang, Charles S Locke, Laura A Williams, Mario Chojkier
BACKGROUND/AIMS: Paricalcitol is highly protein bound, extensively metabolized and eliminated primarily by hepatobiliary excretion. This study was designed to determine if hepatic disease alters the pharmacokinetics or affects the safety of paricalcitol. METHODS: Subjects with mild (n = 5) or moderate (n = 5) hepatic impairment, and subjects with normal hepatic function (n = 10) enrolled in and completed the study. Each subject was administered a single 0.24 microg/kg intravenous dose of paricalcitol, injected within 1 min...
2006: Nephron. Clinical Practice
https://www.readbyqxmd.com/read/16164982/vitamin-d-2-analog-paricalcitol-zemplar-for-treatment-of-myelodysplastic-syndrome
#7
H Phillip Koeffler, Noune Aslanian, James O'Kelly
Myelodysplastic syndrome (MDS) is often a pernicious disorder associated with pancytopenia in the elderly; therapeutic approaches need to balance their toxicities versus the symptoms of the disease. 1,25(OH)(2)-Vitamin-D(3) [1,25(OH)(2)D(3)] inhibits proliferation and induces differentiation of leukemic cells in vitro. Small clinical trials of 1,25(OH)(2)D(3) have shown modest efficacy in MDS; hypercalcemia prevented the administration of doses that have been shown to be effective in vitro. Paricalcitol [19-nor-1,25(OH)(2)D(2), Zemplar] has been approved by the FDA for treatment of secondary hyperparathyroidism...
November 2005: Leukemia Research
https://www.readbyqxmd.com/read/15898824/spotlight-on-paricalcitol-in-secondary-hyperparathyroidism
#8
REVIEW
Dean M Robinson, Lesley J Scott
Paricalcitol (Zemplar) is a synthetic vitamin D2 analog that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in the US pediatric, patients. Paricalcitol effectively reduced elevated serum PTH levels and was generally well tolerated in children and adults with secondary hyperparathyroidism associated with chronic renal failure...
2005: Treatments in Endocrinology
https://www.readbyqxmd.com/read/15733015/paricalcitol-a-review-of-its-use-in-the-management-of-secondary-hyperparathyroidism
#9
REVIEW
Dean M Robinson, Lesley J Scott
Paricalcitol (Zemplar) is a synthetic vitamin D(2) analogue that inhibits the secretion of parathyroid hormone (PTH) through binding to the vitamin D receptor. It is approved in the US and in most European nations for intravenous use in the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure in adult, and in the US paediatric, patients. Paricalcitol effectively reduced elevated serum PTH levels and was generally well tolerated in children and adults with secondary hyperparathyroidism associated with chronic renal failure...
2005: Drugs
https://www.readbyqxmd.com/read/14763069/severe-hyperparathyroidism-despite-paricalcitol-therapy-one-year-follow-up
#10
Suhail B Shuja, Rasib M Raja
Paricalcitol [Zemplar: Abbott Laboratories, Abbott Park, IL, U.S.A.] is efficient for treating secondary hyperparathyroidism in patients on maintenance hemodialysis (HD). Zemplar is thought to be more potent than calcitriol and has been reported to cause less hypercalcemia and hyperphosphatemia. Here, we report a 1-year follow-up on patients from one inner-city dialysis unit. We reviewed the charts of 100 patients and collected data for 1 year. Patients were stratified into four groups depending upon their intact parathormone (iPTH) levels...
2003: Advances in Peritoneal Dialysis
https://www.readbyqxmd.com/read/12915889/1alpha-25-dihydroxyvitamin-d-3-calcitriol-and-its-analogue-19-nor-1alpha-25-oh-2-d-2-potentiate-the-effects-of-ionising-radiation-on-human-prostate-cancer-cells
#11
COMPARATIVE STUDY
N Dunlap, G G Schwartz, D Eads, S D Cramer, A B Sherk, V John, C Koumenis
Radiotherapy with external beam radiation or brachytherapy is an established therapeutic modality for prostate cancer. Approximately 30% of patients with localised prostate cancer relapse at the irradiated site. Secondary effects of ionising radiation (IR), for example, bowel and bladder complications, are common. Thus, the search for biological response modifiers that could potentiate the therapeutic effects of radiation and limit the occurrence of serious side effects is an important task in prostate cancer therapy...
August 18, 2003: British Journal of Cancer
https://www.readbyqxmd.com/read/11689383/therapeutic-uses-of-vitamin-d-analogues
#12
REVIEW
A J Brown
The vitamin D endocrine system has been implicated in numerous biological activities throughout the body. The breadth and magnitude of vitamin D activity suggest potential therapeutic applications for the treatment of several diseases and disorders, including hyperproliferative diseases, immune dysfunction, endocrine disorders, and metabolic bone diseases. However, therapy using natural vitamin D hormone, 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) has been precluded in most cases because of the potent calcemic activity shown by this hormone...
November 2001: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/10633464/new-analogs-of-vitamin-d3
#13
REVIEW
E Slatopolsky, A Dusso, A Brown
Calcitriol, the most active metabolite of vitamin D, controls parathyroid gland growth and suppresses the synthesis and secretion of parathyroid hormone (PTH). However, because of its potent effects on intestinal calcium absorption and bone mobilization, calcitriol treatment can induce hypercalcemia, often precluding its use at therapeutic doses. Hyperphosphatemia is also a persistent problem among patients undergoing chronic hemodialysis and can be aggravated by therapeutic doses of calcitriol. Several pharmaceutical companies were able to modify the side-chain of the 1,25(OH)2D3, allowing some of these new analogs to retain the action on the parathyroid glands while decreasing their hypercalcemic and hyperphosphatemic effects...
December 1999: Kidney International. Supplement
https://www.readbyqxmd.com/read/9808145/therapy-of-secondary-hyperparathyroidism-with-19-nor-1alpha-25-dihydroxyvitamin-d2
#14
RANDOMIZED CONTROLLED TRIAL
K J Martin, E A González, M E Gellens, L L Hamm, H Abboud, J Lindberg
Secondary hyperparathyroidism contributes to significant morbidity in patients with chronic renal failure. The treatment of this disorder with vitamin D compounds, such as calcitriol, although effective at suppressing parathyroid hormone (PTH) secretion, may promote the development of hypercalcemia and hyperphosphatemia, thus increasing the risk for metastatic calcification. A new vitamin D analogue, 19-nor-1alpha,25-(OH)2D2 (paricalcitol; Zemplar, Abbott Laboratories, Inc, Chicago, IL) has recently been developed for the treatment of secondary hyperparathyroidism, and, in experimental animals, it was found to be less calcemic and phosphatemic than calcitriol...
October 1998: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/9808141/vitamin-d-analogues
#15
REVIEW
A J Brown
The plethora of actions attributed to 1,25(OH)2D3 throughout the body have suggested potential therapeutic applications for the treatment of hyperproliferative diseases, immune dysfunction, endocrine disorders, and metabolic bone disease. However, the potent calcemic activity of the natural vitamin D hormone has precluded its use in most cases. New vitamin D analogues are under development that display greater specificity, in most cases, by retaining the therapeutic properties of 1,25(OH)2D3, but with lower calcemic activity...
October 1998: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"